Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.52 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389331 | 0.90 | EPHX2 (0.61) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL10463736 | 0.89 | HTR1A (0.54) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL10464250 | 0.88 | HDAC3 (0.56) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL4304359 | 0.85 | EPHX2 (0.62) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL10461840 | 0.85 | HTR7 (0.55) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL7096246 | 0.84 | HTR1A (0.58) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL14497589 | 0.84 | EPHX2 (0.58) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL4204194 | 0.83 | EPHX2 (0.61) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6225349 | 0.81 | EPHX2 (0.57) | EPHX2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6355408 | 0.80 | EPHX2 (0.57) | EPHX2HTR1ADRD2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560480-B2 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| EP-1727799-B1 | NOVEL ALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | BOEHRINGER INGELHEIM INT (DE) | 2009-01-07 | — | — | EP | disclosed |
| EP-1727812-B1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | BOEHRINGER INGELHEIM INT (DE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1727798-B1 | NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | EP | disclosed |
| US-7262206-B2 | Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| US-7176231-B2 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-13 | — | — | US | disclosed |
| EP-1727798-A1 | NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-06 | — | — | EP | disclosed |
| EP-1727812-A1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-06 | — | — | EP | disclosed |
| EP-1727799-A1 | NOVEL ALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-06 | — | — | EP | disclosed |
| US-20050234120-A1 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| WO-2005087727-A1 | NOVEL ALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
| US-20050209302-A1 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
| WO-2005087761-A1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087726-A1 | NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203104-A1 | Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234120-A1 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3B, GSK3A, CSNK2A3 | EPHX2 3424/4885HTR1A 2543/4885DRD2 4508/4885 |
| US-20050203104-A1 | Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3B, GSK3A, CSNK1G3 | EPHX2 3624/4885HTR1A 3163/4885DRD2 4317/4885 |
| US-20050209302-A1 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3A, GSK3B, PYGL | EPHX2 3566/4885HTR1A 3157/4885DRD2 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.